Related Experiment Video

Updated: May 9, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer

Prachi Walke1,2, Jared D W Price1, Frederick S Vizeacoumar1,3

  • 1Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, S7N 5E5, SK, Canada.

Oncogene
|April 29, 2025
PubMed

Insights

Targeting NEUROG2 shows promise for treating neuroendocrine prostate cancer (NEPC) driven by MYCN overexpression. Depleting NEUROG2 suppressed tumor growth without harming normal cells, offering a new therapeutic avenue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neuroendocrine prostate cancer (NEPC) is aggressive and therapy-resistant.
  • MYCN oncogene overexpression drives NEPC, but direct N-Myc inhibition has failed.
  • Identifying synthetic vulnerabilities of MYCN is crucial for novel NEPC treatments.

Purpose of the Study:

  • To identify therapeutic targets by screening for synthetic vulnerabilities of MYCN in NEPC.
  • To investigate the role of NEUROG2 as a potential therapeutic target in MYCN-driven NEPC.

Main Methods:

  • Unbiased genome-wide screening using isogenic prostate cancer cell lines.
  • Assessment of NEUROG2 depletion effects on MYCN-overexpressing NEPC cells and orthotopic tumor models.
  • Analysis of NEUROG2's role in modulating proneural transcription factors (PTFs).

Main Results:

  • NEUROG2 was identified as a significant synthetic vulnerability of MYCN.
  • NEUROG2 depletion suppressed the growth of MYCN-overexpressing NEPC cells and tumors.
  • NEUROG2 depletion did not affect non-malignant cells.
  • NEUROG2-driven PTF modulation may contribute to NEPC development.

Conclusions:

  • Targeting NEUROG2 presents a promising therapeutic strategy for MYCN-overexpressing NEPC.
  • NEUROG2 is a critical factor in the progression of NEPC driven by MYCN.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K